Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01274533 · ClinicalTrials.gov registry record · Phase 2

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

A Phase 2 study of Adult T-cell Leukemia/Lymphoma, sponsored by Columbia University.

Completed
Registry status
Phase 2
Development phase
4
Enrollment target
1
Study location

NCT01274533: Completed Phase 2 study of Adult T-cell Leukemia/Lymphoma, sponsored by Columbia University.

NCT01274533 is a Phase 2 study of Adult T-cell Leukemia/Lymphoma that has completed, run by Columbia University. The registered enrollment target is 4 participants, below the 53-participant average among 8 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01274533, a Phase 2 study of Adult T-cell Leukemia/Lymphoma, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 2
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1. Currently, there is no accepted standard therapy for this disease. The purpose of this research study is to evaluate the use of the investigational drug lenalidomide in the treatment of Adult T cell Leukemia/Lymphoma. Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment of specific types of myelodysplastic syndrome (MDS) and in combination with dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM are cancers of the blood. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental.

Primary Outcome

Peripheral blood, CT or MRI

Conditions Studied

Adult T-cell Leukemia/Lymphoma

Interventions

  • DRUG Lenalidomide

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2010-12
Est. Completion 2013-05
Phase Phase 2
Columbia University

958 total trials

What the finished NCT01274533 record still lists

NCT01274533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 8 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Adult T-cell Leukemia/Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.

NCT01274533 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01274533 about?

NCT01274533 is a clinical study titled "Lenalidomide in HTLV-1 Adult T-Cell Leukemia". This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1. Currently, there is no accepted standard therapy for this disease. The purpose of this research study is to evaluate the use ...

What is the current status of trial NCT01274533?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-12. Estimated completion is 2013-05.

What conditions does trial NCT01274533 study?

This clinical trial studies the following conditions: Adult T-cell Leukemia/Lymphoma.

What interventions are being tested in trial NCT01274533?

The interventions under investigation include: Lenalidomide (DRUG).

Who is sponsoring clinical trial NCT01274533?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01274533 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adult T-cell Leukemia/Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01274533's enrollment target sits among peer trials

4 9th of 8 the lowest of 8 other Adult T-cell Leukemia/Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adult T-cell Leukemia/Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01274533, the US trial registry maintained by the National Library of Medicine. NCT01274533 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.